Celldex Therapeutics is a clinical stage biotechnology company that is dedicated to developing monoclonal and bispecific antibodies to address devastating diseases that currently have inadequate treatment options. Their pipeline consists of antibody-based therapeutics that can engage the human immune system and directly impact critical pathways, with the goal of improving the lives of patients suffering from inflammatory diseases and various forms of cancer. Led by a strong management team, including Founder, President, Chief Executive Officer, and Director Anthony S.

Marucci, and Founder, Executive Vice President, and Chief Scientific Officer Tibor Keler, Ph. D., Celldex Therapeutics is committed to advancing the field of antibody-based therapeutics. They aim to provide innovative solutions that tackle the root causes of diseases and offer new hope to patients.

By harnessing the power of antibodies and their expertise in scientific research, Celldex Therapeutics is at the forefront of developing groundbreaking treatments for those in need